LymphoStats

The Lymphoma Biostatistics and Data Science Laboratory develops and validates statistical models to help assess risk and guide prognoses. These models and tools have been developed by the lab or in collaboration with lab members.

Prognostic models

Diffuse large B-cell lymphoma

  1. Newly diagnosed. The IPI24 model provides a 0% to 100% probability of a patient achieving 24 months of event-free survival after diagnosis.

    Publication: Maurer MJ, Jais JP, Ghesquières H, Witzig TE, Hong F, Haioun C, Thompson CA, Thieblemont C, Micallef IN, Porrata LF, Ribrag V, Nowakowski GS, Casasnovas O, Bologna S, Morschhauser F, Morrison VA, Peterson BA, Macon WR, Copie-Bergman C, Feldman AL, Syrbu SI, Kurtin PJ, Gascoyne RD, Li H, Allmer C, Kahl BS, Ansell SM, Slager SL, Link BK, Salles G, Habermann TM, Tilly H, Cerhan JR. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. American Journal of Hematology. 2016; doi:10.1002/ajh.24223.

  2. Relapsed-refractory. This prognostic tool provides information on survival at the time of first progression or relapse for patients with diffuse large B-cell lymphoma who were treated with the front-line R-CHOP chemotherapy drug combination or anthracycline-based immunochemotherapy. R-CHOP stands for rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.

    Publication: Maurer MJ, Jakobsen LH, Mwangi R, Schmitz N, Farooq U, Flowers CR, de Nully Brown P, Thompson CA, Frederiksen H, Cunningham D, Jørgensen J, Poeschel V, Nowakowski G, Seymour JF, Merli F, Haioun C, Ghesquieres H, Ziepert M, Tilly H, Salles G, Shi Q, El-Galaly TC, Habermann TM. Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. American Journal of Hematology. 2021; doi:10.1002/ajh.26149.

Follicular lymphoma

  1. Newly diagnosed. The FLIPI24 model calculates the percentage of probability of an event — progression, retreatment, transformation or death — within the first two years after starting front-line immunochemotherapy.

Mantle cell lymphoma

  1. Relapsed-refractory. The 2L BTKi MIPI model is a prognostic index estimating two-year, progression-free survival in patients with relapsed-refractory mantle cell lymphoma who initiate second-line covalent Bruton tyrosine kinase inhibitor (BTKi) monotherapy.

    Publication: Villa D, Jiang A, Visco C, Crosbie N, McCulloch R, Buege MJ, Kumar A, Bond DA, Paludo J, Maurer MJ, Thanarajasingam G, Lewis KL, Cheah CY, Baech J, El-Galaly TC, Kugathasan L, Scott DW, Gerrie AS, Lewis D. Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. Blood Advances. 2023; doi:10.1182/bloodadvances.2023009804.

Hodgkin lymphoma — Newly diagnosed

  1. Early stage. The E-HIPI tool calculates the percentage of probability of progression or death within the first two years after starting front-line chemotherapy for early-stage Hodgkin lymphoma.

  2. Advanced stage. The A-HIPI tool calculates the percentage of probability of progression or death within the first five years after starting front-line chemotherapy for advanced-stage Hodgkin lymphoma.

    Publication: Rodday AM, Parsons SK, Upshaw JN, Friedberg JW, Gallamini A, Hawkes E, Hodgson D, Johnson P, Link BK, Mou E, Savage KJ, Zinzani PL, Maurer M, Evens AM. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and validation of a clinical prediction model from the HoLISTIC Consortium. Journal of Clinical Oncology. 2023; doi:10.1200/JCO.22.02473.

  3. Nodular lymphocyte-predominant Hodgkin lymphoma. The lymphocyte-predominant international prognostic score (LP-IPS) was developed to identify patients at high risk and inform upcoming prospective clinical trials evaluating de-escalation of therapy for patients with low LP-IPS scores (< 2).

    Publication: Binkley MS, Flerlage JE, Savage KJ, Akhtar S, Steiner R, Zhang XY, Dickinson M, Prica A, Major A, Hendrickson PG, Hopkins D, Ng A, Casulo C, Baron J, Roberts KB, Al Kendi J, Balogh A, Ricardi U, Torka P, Specht L, De Silva R, Pickard K, Blazin LJ, Henry M, Smith CM, Halperin D, Brady J, Brennan B, Senchenko MA, Reeves M, Hoppe BS, Terezakis S, Talaulikar D, Picardi M, Kirova Y, Fergusson P, Hawkes EA, Lee D, Doo NW, Barraclough A, Cheah CY, Ku M, Hamad N, Mutsando H, Gilbertson M, Marconi T, Viiala N, Maurer MJ, Eichenauer DA, Hoppe RT; GLOW Consortium. International prognostic score for nodular lymphocyte-predominant Hodgkin lymphoma. Journal of Clinical Oncology. 2024; doi:10.1200/JCO.23.01655.

Clinical trial design tools

Diffuse large B-cell lymphoma

These interactive tools allow users to assess different cutoffs for laboratory-based exclusion criteria and their impact on clinical trial eligibility for patients with newly diagnosed diffuse large B-cell lymphoma:

Follicular lymphoma

This interactive tool shows patterns of care in patients with relapsed-refractory follicular lymphoma who have received at least three lines of therapy.

Publication: Casulo C, Larson MC, Lunde JJ, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan J, Flowers CR, Link BK, Maurer MJ. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): A multicentre cohort study. The Lancet Haematology. 2022; doi:10.1016/S2352-3026(22)00033-3.

Hodgkin lymphoma

This interactive tool allows users to define risk groups based on the A-HIPI prognostic model in advanced-stage Hodgkin lymphoma. This can be useful in designing and computing sample size for clinical trials.

Publication: Maurer MJ, Parsons SK, Upshaw JN, Rodday AM, Mwangi R, Rossetti S, Friedberg JW, Gallamini A, Federico M, Hawkes EA, Hodgson D, Johnson PWM, Link BL, Mou E, Savage KJ, Zinzani PL, Evens AM. The A-HIPI prediction model in advanced stage Hodgkin lymphoma: Identification of risk groups and creation of an online tool. Blood Advances. 2025; doi:10.1182/bloodadvances.2024014689.